about
Endopolyploidy in irradiated p53-deficient tumour cell lines: persistence of cell division activity in giant cells expressing Aurora-B kinaseObinutuzumab in hematologic malignancies: lessons learned to dateThe abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevantNovel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage.Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studySegregation of genomes in polyploid tumour cells following mitotic catastrophe.Anti-Yo antibody-positive cerebellar degeneration associated with endometrial carcinoma: case report and review of the literature.Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor modelsAnti-CD 40 monoclonal antibody.Radiotherapy physics research in the UK: challenges and proposed solutions.Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune responseBrentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK centerBreast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors.Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.Current treatment approaches for diffuse large B-cell lymphoma.How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?New insights into the mechanisms of action of radioimmunotherapy in lymphoma.A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity.Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.The future of anti-CD20 monoclonal antibodies: are we making progress?New antibody drug treatments for lymphoma.Radioimmunotherapy in follicular lymphoma.Guidelines for preclinical and early phase clinical assessment of novel radiosensitisersU.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.XVII. Radiotherapy in early stage Hodgkin lymphoma.Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy.Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.Update on obinutuzumab in the treatment of B-cell malignancies.Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.Immuno-regulatory antibodies for the treatment of cancer.Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling.Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?Clinical development of new drug-radiotherapy combinations.
P50
Q24650663-8146E583-03CC-4CDE-B12B-91195D2CF1A3Q26799205-FBD76628-CFB5-4D2C-90F3-1F28544B7248Q28081732-F23FF314-6519-4639-A48F-AC039FAABD2FQ30500362-1F5378D9-DB8A-4F6A-AC2E-CEC8A6077183Q33401346-7A76E6FF-E4CF-4858-B5ED-DE20C50B0A1EQ33915750-627ECA95-E660-48A7-A21F-A8BAF2AD9F78Q34226010-7F880E97-EDFB-4EBA-AA41-232F4A61AFFFQ34470954-659D12D0-6289-464E-979B-87A65A192BDBQ34515075-FCB351AB-4F11-455C-B953-276A0ADEC96FQ34664223-2A673BE4-DD1F-4747-AB35-6392DFFB027AQ34853959-4B931865-E4A3-484C-8E6C-9AF866EAEFB3Q36221538-FA8B7CC7-C51C-4404-A6A7-98282B7CC254Q36325879-9CA2EF16-4186-4E71-BD40-203EDF013267Q36529941-D75C24ED-7FD7-4D5E-8F2C-D4BAB0102DD7Q36747309-1A953868-42C9-408A-8ACE-F16E113D36E6Q36862523-E634E428-2B68-4CD6-99E0-CF1FE9FFCCD4Q36924721-C11EBCA5-3790-4413-92EB-F0220381ABAFQ37056894-F9D86B38-E716-46C5-9AB9-B70AF6BBF2BEQ37132898-4DBEBDEF-F504-4C5F-B973-8907FA6C2422Q37208506-E267A82E-2C49-4592-A8EE-2A5566191341Q37222783-DCAB3A78-A15E-4956-8510-53E910B4D9AFQ37322979-5960A041-7766-421E-B1B3-D56ACEF0BEBFQ37323004-6EED3976-98C0-48CC-BBF4-7A33F77EFF0EQ37826312-5DC11448-03EC-402B-8CAA-6D066EDFAE8BQ37852003-A95FAEA1-E22A-429F-A624-62832E1A3B2FQ37887152-434E6AC6-A194-47E7-932A-276FB99CD7B9Q37902873-4BFD4A39-CECF-40FD-8373-E91DA44159C8Q38042090-6D4314CE-4CD9-4065-8CA2-30D4C153BC19Q38115238-5AC97AA8-3DB4-4A04-817A-974855907738Q38116144-17ECC02E-F364-423C-BF4A-F43E85EC7895Q38193943-271FF62C-570F-4988-A02E-772CFC9D9778Q38218949-A3884E3C-8730-4069-9FC9-6356D5EE22CCQ38246230-4E7664AE-160F-4A04-B39C-B9584CAA0EE2Q38396244-CE9DA0E5-6F3E-47AD-B5B8-626B518A38CDQ38424617-DA37D86E-31B8-4E9F-8B1C-14E24BEABBDBQ38428316-CAF92042-4397-4DA8-A7C3-0E3F699EE1EFQ38770022-6B7A8E31-ECB5-4001-ADB4-7A101B528461Q38828265-3338C5B6-A86A-47AF-AD28-043BCA72D8DFQ38831848-29CA125C-D38C-4114-B248-02033EE5C3C7Q38849191-0A068A69-28D3-4BC9-A7E8-D192E6D58D20
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Tim M Illidge
@nl
Tim M Illidge
@sl
Tim M. Illidge
@en
Tim M. Illidge
@es
type
label
Tim M Illidge
@nl
Tim M Illidge
@sl
Tim M. Illidge
@en
Tim M. Illidge
@es
prefLabel
Tim M Illidge
@nl
Tim M Illidge
@sl
Tim M. Illidge
@en
Tim M. Illidge
@es
P1006
P214
P244
P1006
P1053
M-3659-2015
P106
P1153
6701805178
P21
P213
0000 0001 2416 3339
P214
P244
n2004124163
P31
P3829
P496
0000-0003-3191-7324
P569
1950-01-01T00:00:00Z
P734
P735
P7859
lccn-n2004124163